The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
2.
MAGL INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
The present invention belongs to the field of medicine, and relates to a compound
The present invention belongs to the field of medicine, and relates to a compound
The present invention belongs to the field of medicine, and relates to a compound
of Formula I and a pharmaceutically acceptable salt thereof for using as a MAGL inhibitor, as well as a preparation method and use thereof, and an intermediate for preparing the same.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
3.
OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF
The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, and in particular to a 2-cyano-3,12-dioxoolean-1,9(11)-dien-17-phenylacrylamide derivative and a preparation method thereof; and the present invention further relates to use of the novel compound in the preparation of an anticancer medicament.
The use of a Jingfang preparation in the preparation of a drug or health care product for preventing or treating diabetes and/or diabetic complications. The Jingfang preparation is prepared from notopterygium rhizoma et radix, angelicae pubescentis radix, poria, saposhnikoviae radix, schizonepetae herba, chuanxiong rhizoma, platycodonis radix, bupleuri radix, peucedani radix, aurantii fructus and glycyrrhizae radix et rhizoma. The preparation not only has the effect of reducing blood sugar in a diabetic model rat and increasing the sugar tolerance of the diabetic rat, but can also prevent and improve various diabetic complications, such as diabetic cardiomyopathy and diabetic fundus diseases.
Use of MAGLZ-II-11 in the preparation of a medicament for preventing or treating fatty liver diseases. MAGLZ-Ⅱ-11 can significantly reduce the body weight and liver indexes in non-alcoholic fatty liver disease patients, reduce the levels of serum glutamic pyruvic transaminase and glutamic oxalacetic transaminase, and reduce the levels of free fatty acids and triglycerides in liver homogenates, having significant effects in the treatment of non-alcoholic fatty liver diseases and having good therapeutic effects and high safety. MAGLZ-II-11 has significant therapeutic effects on alcoholic fatty liver, and has significant lipid-lowering and liver-protecting effects.
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention relates to the field of medicine, and sets forth a use of MAGLZ-II-11 in the preparation of a drug for preventing or treating hepatitis or liver fibrosis. The purpose of the present invention is to provide an application of the compound of the present invention in the preparation of a drug for preventing or treating hepatitis, and same has a good therapeutic effect and good safety. The MAGLZ-II-11 of the present invention can reduce alanine aminotransferase and aspartate aminotransferase in hepatitis patients. The MAGLZ-II-11 of the present invention is used for the treatment of immune hepatitis, drug-induced hepatitis, chemical hepatitis or viral hepatitis, has a significant therapeutic effect, and has a significant therapeutic effect on liver fibrosis.
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
7.
LIQUID PREPARATION OF RECOMBINANT HUMANIZED ANTI-PD-1 MONOCLONAL ANTIBODY
A liquid preparation of a recombinant humanized anti-PD-1 monoclonal antibody. The liquid preparation contains 10 mg/ml of an aglycosylated anti-PD-1 monoclonal antibody, 10-20 mM of a buffer, 220-270 mM of a stabilizer, and 0.02-0.06%(w/v) of a solubilizer, and a buffer system regulates the pH to 5.5-6.5. By further optimizing the content of the buffer solution, the stabilizer, and the solubilizer, the liquid preparation suitable for intravenous administration is provided, can maintain stability during storage, and has lower specificity and fragmentation. After the preparation is placed at 2-8ºC for 24 months, the appearance, concentration, and pH of the preparation and the purity and charge heterogeneity of an antibody are not obviously changed.
APPLICATION OF CHINESE THOROWAX ROOT-HONEYSUCKLE FLOWER FORMULATION IN PREPARING ANTI-CORONAVIRUS DRUG AND PREPARATION METHOD FOR CHINESE THOROWAX ROOT-HONEYSUCKLE FLOWER FORMULATION
An application of a Chinese thorowax root-honeysuckle flower formulation in preparing an anti-coronavirus drug and a preparation method for the Chinese thorowax root-honeysuckle flower formulation. The Chinese thorowax root-honeysuckle flower formulation is prepared from Chinese thorowax roots, honeysuckle flowers, baikal skullcap roots, kudzuvine roots, fineleaf schizonepeta herbs, sweet wormwood herbs, weeping forsythia capsules, platycodon roots, bitter apricot seeds, peppermints, and heartleaf houttuynia herbs, has the effects of clearing heat and releasing the exterior, dispersing the lung and discharging heat, and reducing phlegm and relieving sore-throat and cough. The drug can significantly reduce lung indexes of syndrome of human coronavirus pneumonia epidemic toxins attacking the lung, and significantly increase the percentages of CD4+T lymphocytes, CD8+T lymphocytes, and total B lymphocytes in the peripheral blood of mice with the syndrome of human coronavirus pneumonia epidemic toxins attacking the lung. Experiments prove that the drug has a definite anti-human coronavirus effect.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/22 - Sustained or differential release type
A61K 9/52 - Sustained or differential release type
Disclosed is a method for preparing a milrinone intermediate, relating to the technical field of drug synthesis. A solid compound intermediate I is reacted with alkyl orthoformate to obtain a milrinone intermediate II. Moreover, also provided is a method for preparing milrinone by using the milrinone intermediate II. The method is convenient in operation, high in safety, and high in yield, and is suitable for industrial scale-up production. The appearance and purity of the obtained milrinone product are up to the standard.
C07D 211/82 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
A use of anhydroicaritin in preparing a medicine for preventing and treating hemorrhagic disorders, and which relates to the field of medicine. The anhydroicaritin may improve platelet dysfunction, shorten the time of thromboplastin, promote blood clotting and may be used for the prevention and treatment of hemorrhagic disorders, especially cerebral infarction hemorrhage transformation, gastrointestinal hemorrhages caused by cerebral infarction thrombolytic drugs or antithrombotic drugs or the treatment of bleeding complications of myocardial infarction thrombolytic drugs or antithrombotic drugs.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A use of anhydroicaritin in preparing a medicine for preventing and treating hemorrhagic disorders, and which relates to the field of medicine. The anhydroicaritin may improve platelet dysfunction, shorten the time of thromboplastin, promote blood clotting and may be used for the prevention and treatment of hemorrhagic disorders, especially cerebral infarction hemorrhage transformation, gastrointestinal hemorrhages caused by cerebral infarction thrombolytic drugs or antithrombotic drugs or the treatment of bleeding complications of myocardial infarction thrombolytic drugs or antithrombotic drugs.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention relates to the field of pharmaceutical chemistry and the field of pharmacotherapeutics, and in particular, to a 2-cyano-3,12-dioxooleanane-1,9(11)-diene-17-cinnamamide derivative and a preparation method therefor; and the present invention further relates to an application of a novel compound in preparation of anti-cancer drugs.
C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A composition containing lactic acid bacteria and use thereof. The composition contains Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium bifidum, resistant dextrin, maltodextrin, corn starch, inulin, stachyose and other components. The composition can regulate the intestinal microecological balance, and have a significant improvement effect on abdominal pain, abdominal distension, diarrhea, and constipation, and can alleviate discomforts caused by taking Orlistat and other drugs.
Use of a traditional Chinese medicine composition in the preparation of drugs for treating traumatic injury. The traditional Chinese medicine composition is mainly prepared from lonicera japonica, hedyotis diffusa, radix scrophulariae, asarum sagittarioides, radix rehmanniae, radix paeoniae alba, radix angelica sinensis, liquorice, centipede, caulis sinomenii, and pyrola. It has been proved by zoological experiments that the traditional Chinese medicine composition can effectively reduce various inflammatory factors in injured parts of soft tissues in rats, and relieve the symptoms such as swelling and ecchymosis in the injured parts of the rats. Clinical experiments show that the traditional Chinese medicine composition can effectively alleviate the clinical symptoms of patients with soft tissue injury, and the effective rate of treatment can reach 95% or more.
Disclosed is a novel use of a Chinese medicine composition, specifically relating to a use of a Chinese medicine composition in preparing a medicine for treating stroke. The Chinese medicine composition is mainly prepared from raw materials such as leech, scorpion, centipede, angelica sinensis, scrophularia ningpoensis, coix lacryma-jobi, phellodendron amurense, lonicera japonica, astragalus, glycyrrhiza uralensis, etc. In addition, the Chinese medicine composition can also contain stractylodes lancea and paeonia sterniana. The pharmacological test results show that the Chinese medicine composition can effectively reduce secondary brain tissue damage of a cerebral hemorrhage, improve the behavior of rats with cerebral hemorrhage and stroke as well as neurological function after a cerebral hemorrhage, and has the effect of protecting the brain tissue of rats with ischemic stroke and improving blood stasis symptoms thereof.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
16.
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREPARING DRUGS FOR TREATING EDEMA
A traditional Chinese medicine composition and an application thereof. The traditional Chinese medicine composition is prepared from Fructus Aurantii Immaturus, Rhizoma Atractylodis Macrocephalae, Radix Ginseng, Fructus Lycii, Colla Corii Asini, Radix Polygoni Multiflori, Semen Cassiae, and Aloe. Pharmacological experiments show that: the traditional Chinese medicine composition has good regulation effects on the thyroid level, the content of urinary protein, cyclic nucleotide system, serum protein and lipid levels in rats with edema, has significant differences by comparing with a model group, and has a good therapeutic effect on edema caused by various reasons.
The present invention relates to the field of medicines, and relates to a compound represented by formula (I) and acting as a MAGL inhibitor and a pharmaceutically acceptable salt thereof, a preparation method therefor, use thereof, and an intermediate for preparing same.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
18.
TRADITIONAL CHINESE AND WESTERN MEDICINE COMPOSITION FOR TREATING OSTEOARTHRITIS
A traditional Chinese and western medicine composition for treating osteoarthritis, being mainly prepared from Astragalus membranaceus, honeysuckle, golden cypress, Atractylodis rhizoma, coix seed, Scrophularia ningpoensis, Angelica sinensis, Radix paeoniae alba, liquorice, hirudo, centipede, scorpion and celecoxib. Animal tests show that the traditional Chinese and western medicine composition has therapeutic effects on joint diseases, especially osteoarthritis, and can reduce inflammatory factors, reduce inflammation, enlarge the movement range of diseased joints, and reduce the swelling thickness of a synovial membrane.
A61K 35/62 - LeechesWorms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
19.
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING OSTEOARTHRITIS
A traditional Chinese medicine composition for treating osteoarthritis, comprising medicinal materials such as Astragalus membranaceus, honeysuckle, golden cypress, Atractylodis rhizoma, coix seed, Scrophularia ningpoensis, Angelica sinensis, Radix paeoniae alba, liquorice, hirudo, centipede and scorpion. Animal and clinical tests show that the traditional Chinese medicine composition has good therapeutic effects on joint diseases, especially osteoarthritis, can significantly reduce inflammatory factors, reduce inflammation, significantly improve clinical symptoms, and improve the quality of life of patients, and is suitable for further promotion and application.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A combination drug for treating osteoarthritis, relating to the field of medicine. The combination drug comprises celecoxib, and one of vein-dredging pills or vein-dredging granules. The vein-dredging pills or vein-dredging granules are prepared by radix astragali, flos lonicerae, cortex phellodendri, rhizoma atractylodis, semen coicis, radix scrophulariae, radix angelicae sinensis, radix paeoniae alba, radix glycyrrhizae, hirudo, scolopendra, scorpio, and other medicinal materials. Animal and clinical experiments show that the combination drug has a good therapeutic effect on joint diseases, particularly osteoarthritis, can obviously reduce inflammatory factors, reduce inflammatory response, obviously improve clinical symptoms, and improve the quality of life of patients, and is suitable for further promotion and use.
The present invention relates to the field of medicines, and relates to a compound represented by formula (I) and acting as a MAGL inhibitor and a pharmaceutically acceptable salt thereof, a preparation method therefor, use thereof, and an intermediate for preparing same.
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation:
3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.
The present application relates to a method of icaritin in preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 9/00 - Medicinal preparations characterised by special physical form
Disclosed are a compound represented by the general formula (I), or a stereisomer, a tautomer, a derivative, a prodrug or a pharmaceutically acceptable salt thereof, and a method for preparing the compound and the use of the compound in preparing a drug for treating neuropathic pain and/or neuropathic pain syndrome or an anti-inflammatory drug: see (I), wherein R1is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2and R3are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2and R3are not hydrogen at the same time; furthermore, when either R2or R3is nitro or halogen, the other two of R1, R2and R3 are not hydrogen at the same time. The compound has a good effect on the treatment of neuropathic pain and/or neuropathic pain syndrome and a good anti-inflammatory effect, without side effects such as addiction.
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/547 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
A61P 25/04 - Centrally acting analgesics, e.g. opioids
The present invention relates to the field of pharmaceuticals, and in particular to a guanidine derivative containing a furan structure and a composition thereof. The derivative and the composition thereof can be used for preparing pharmaceuticals for treating pathological feature diseases having indoleamine 2,3-dioxygenase mediated tryptophan metabolic pathways. The present invention further relates to a method for preparing the derivative and a midbody thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A fusion protein of hFGF21 or its analogs having improved pharmaceutical properties, and use of the fusion protein in preparing medicines for treating diseases, such as diabetes, obesity, non-alcoholic fatty liver disease, dyslipidemia, and/or metabolic syndrome.
Provided are an imidazole derivative containing a bridge ring, and a composition thereof. The imidazole derivative and the composition thereof can be used in the preparation of drugs for treating pathological characteristic diseases that is mediated by indoleamine2,3-dioxygenase and that is related to in the tryptophan metabolism field. Also provided is a method for preparing the derivative and an intermediate thereof.
The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
The present application relates to the use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Zingiberis rhizoma or an extract of the above mixed herbal medicine; (2) one or more chemotherapeutic compounds. The present invention also discloses use of the above pharmaceutical composition in the preparation of medicament for treating human cancer and in the preparation of medicament for reducing side effects of chemotherapeutic compounds in human body. The pharmaceutical composition of the present invention can reduce chemotherapy-induced peripheral neuropathic side effects such as limb paresthesia, pain, cold skin, formication, powerlessness and the like, increase tolerance dosages of anticancer drugs, and enhance efficacy of anticancer drugs.
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (China)
Inventor
Zhang, Chun
Fan, Kai
Ma, Xuefeng
Yang, Li
Hu, Chunlan
Luo, Hua
Mei, Xiang
Abstract
Provided are a PEGylated analogue protein of canine urate oxidase, preparation method and use thereof. The analogue protein of canine urate oxidase is a canine urate oxidase, or a chimeric protein comprising part of the amino acid sequence of a canine urate oxidase and part of the amino acid sequence of a human urate oxidase, or a mutant protein thereof. The PEGylated analogue protein of canine urate oxidase and pharmaceutical compositions thereof according to the present invention can be used for the prevention and/or treatment of hyperuricemia and chronic gout.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 9/96 - Stabilising an enzyme by forming an adduct or a compositionForming enzyme conjugates
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C12N 9/06 - Oxidoreductases (1.), e.g. luciferase acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (China)
Inventor
Fan, Kai
Zhao, Zhiquan
Chen, Yong
Zhang, Chun
Wang, Lin
Abstract
Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs.
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (China)
Inventor
Fan, Kai
Zhang, Chun
Ma, Xuefeng
Mei, Xiang
Hu, Chunlan
Abstract
The present invention provides a humanized recombinant uricase and mutants thereof, wherein the humanized recombinant uricase is a chimeric protein which comprises amino acids of non-human mammal uricase and amino acids of human uricase. The humanized recombinant unease and mutants thereof have reduced immunogenicity in human, and can be used for the treatment of hyperuricemia and gout.
Provided are applications of arctigenin in formulating medicines for preventing or treating diseases related to blood cell reduction, and preparations that contain arctigenin, particularly micro-emulsions that contain arctigenin. Experiments show that arctigenin can significantly increase the white cell counts after chemotherapy, especially the neutrophil granulocyte counts.
A microemulsion formulation contains arctigenin and microemulsion carriers, said microemulsion carriers comprise oil phase and emulsifier, and the microemulsion has an average particle size of 10-90 nm.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A bilayer matrix slow release tablet which comprises slow release layer containing metoprolol succinate and an auxiliary layer assisting in regulating drug release rate is disclosed.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (China)
Inventor
Fan, Kai
Zhao, Zhiquan
Abstract
A chimeric protein containing neutrophil inhibitory factor and hirugen, the chimeric protein having an amino acid sequence that includes FPRPGSGG (SEQ ID NO:21) Also provided is a pharmaceutical composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, or for inhibiting platelet aggregation.
The present invention provides the hydrosulfate of prasugrel as follows of formular (ii), pharmaceutical combination and uses thereof. The hydrosulfate of prasugrel provided by the invention has good stability, good peroral absorbability, good metabolism activity and platelet aggregation inhibition, low toxicity. Therefore it is a promising anticoagulant for treating and preventing diseases associated with thrombosis and infarction.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
The present invention provides a pharmaceutical composition comprising active components as followed: amlodipine or pharmaceutically acceptable salts, pioglitazone or pharmaceutically acceptable salts, and rosuvastatin or pharmaceutically acceptable salts. The present invention also provides use of the pharmaceutical composition in the manufacture of medicaments for treating hypertension and metabolic syndrome. The pharmaceutical composition can effectively control occurrence of related cardiovascular diseases during treating hypertension and metabolic syndrome, and improve survival prognosis in hypertensive patients. When blood pressure reaches target level, the risk factors such as cardiovascular diseases are retrieved, metabolic disorder and prognosis of patients are improved, and survival rate of hypertensive patients is raised.
A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
The present invention provides a pharmaceutical composition comprising active components as followed: 1) angiotensin II receptor inhibitors or pharmaceutically acceptable salts, 2) pioglitazone or pharmaceutically acceptable salts, and 3) rosuvastatin or pharmaceutically acceptable salts. The present invention also provides use of the pharmaceutical composition in the manufacture of medicaments for treating hypertension and metabolic syndrome. The pharmaceutical composition can effectively control occurrence of related cardiovascular diseases during treating hypertension and metabolic syndrome, and improve survival prognosis in hypertensive patients. When blood pressure reaches target level, the risk factors such as cardiovascular diseases are retrieved, metabolic disorder and prognosis of patients are improved, and survival rate of hypertensive patients is raised.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
The invention provides a method of synthesizing sevoflurane. The method comprises the following steps that: taking hexafluoro isopropanol as the raw material and reacting it with trioxymethylene (or paraformaldehyde) in the presence of acids to generate di-hexafluoro isopropanol formal derivatives, adding anhydrous aluminum trihalide to generate halomethyl 2, 2,2-trifluoro-1-(trifluoromethyl) ethyl ether, then reacting the halomethyl compound with metal fluoride to form the sevoflurane. The method has low cost, and the reaction condition is easy to implement, and produces sevoflurane in large scale.
Provided is a chimeric protein comprising neutrophil inhibitory factor, the peptide FPRP specially recognizing the thrombin active site and hirugen. Also provided is the medicament composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, inhibiting platelet aggregation etc.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/815 - Protease inhibitors from leeches, e.g. hirudin, eglin
patents
